Related Experiment Video
Updated: Nov 14, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis
Guocan Yu1, Qingshan Cai1, Xudong Xu1
1Zhejiang Tuberculosis Diagnosis and Treatment Center, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Background:
Small cell lung cancer (SCLC) is a highly malignant lung cancer with a very poor prognosis. Clinical treatment options for SCLC are still limited, especially for patients who have failed first or second line therapy. Anlotinib is a potentially beneficial new treatment option for SCLC. The aim of this meta-analysis is to evaluate the efficacy and safety of anlotinib-containing regimen for the treatment of SCLC.
Methods:
We will search SinoMed, Wanfang Database, China National Knowledge Infrastructure, Embase, Cochrane Library, and PubMed for relevant articles that may meet the criteria published before March 31, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of anlotinib-containing regimen for the treatment of SCLC. Clinical randomized controlled trials comparing anlotinib-containing regimens with other treatment regimens for advanced SCLC will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data.
Results:
The results of this study will provide evidence of anlotinib-containing regimens for advanced SCLC, and provide clinicians and patients with another convenient and effective treatment regimen for SCLC. This meta-analysis will be submitted to a peer-reviewed journal for publication.
Conclusion:
This meta-analysis will provide clinical evidence of anlotinib-containing regimens for advanced SCLC, which may or may not be found for anlotinib use.
Systematic Review Registration:
INPLASY202110034.
Insights
This meta-analysis evaluates anlotinib for advanced small cell lung cancer (SCLC). Anlotinib-containing regimens show potential as an effective treatment option for SCLC patients, especially after initial therapies fail.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Small cell lung cancer (SCLC) presents a significant clinical challenge due to its high malignancy and limited treatment options.
- Prognosis for SCLC remains poor, particularly for patients refractory to first or second-line therapies.
- Anlotinib emerges as a potential therapeutic agent for SCLC management.
Purpose of the Study:
- To conduct a meta-analysis assessing the efficacy and safety of anlotinib-containing regimens in SCLC treatment.
- To provide evidence-based support for anlotinib as a treatment option for advanced SCLC.
Main Methods:
- Systematic literature search across multiple databases (SinoMed, Wanfang, CNKI, Embase, Cochrane, PubMed) up to March 31, 2021.
- Inclusion of clinical randomized controlled trials comparing anlotinib regimens with other treatments for advanced SCLC.
- Risk of bias assessment using the Cochrane Handbook and statistical analysis with RevMan 5.3 software.
Main Results:
- The study aims to present findings on the effectiveness of anlotinib-based treatments.
- Results will detail the safety profile of anlotinib in the context of SCLC therapy.
Conclusions:
- This meta-analysis will offer crucial clinical evidence for anlotinib-containing regimens in advanced SCLC.
- Findings may guide clinicians and patients towards a new, effective treatment strategy for SCLC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
